Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Molecules versus cells for Hodgkin lymphoma management

Stephen Ansell • 11 Dec 2021
ASH 2021
Hodgkin Lymphoma Lymphoma Antibodies CAR-T

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, discusses the use of immunological molecules versus cellular therapy in the management of Hodgkin Lymphoma. A plethora of data is emerging that demonstrates the potential of numerous agents, including CAR T-cells, bispecific antibodies, and other immunologically active agents. Prof. Ansell comments that currently, one category has not shown to be superior than the other, with exciting data coming out to support the use of both. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Stephen Ansell

MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
1:03
What’s on the horizon for Hodgkin lymphoma?
Stephen Ansell • 11 Dec 2023
0:51
Treating patients with Hodgkin lymphoma who are chemo-resistant
Stephen Ansell • 11 Dec 2023
1:21
Hodgkin lymphoma highlights from ASH 2023: nivo-AVD versus BV-AVD in patients with HL
Stephen Ansell • 11 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals